dm+d

395273005

Articles

Insulin preparations: RMOC recommendations of safety considerations for formulary decision making

22 June 2018At its meeting on 18th April 2018 the Regional Medicines Optimisation Committee (RMOC) (Midlands and East) reviewed issues pertaining to safety considerations when adopting any…
Search Articles

Refrigerated Storage

NovoMix 30Novo Nordisk

Novo Nordisk
NovoMix 30
Injection (penfills and pens), 100 units/ml

In the event of an inadvertent temperature excursion the following data may be used:
The penfills and pens are stable when exposed to temperatures <30°C for 28 days.

Please refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Following the excursion, store the product outside of the fridge (<30°C)
25 January 2022
London MI Service

New Medicines

Truvelog Mix 30 Type 1 and 2 diabetes mellitus in adults, adolescents and children aged ≥10 years.

Information

Truvelog Mix 30
Biosimilar
Sanofi
Sanofi

Development and Regulatory status

None
Recommended for approval (Positive opinion)
None
Feb 22Recommended for EU approval by CHMP “for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above”. Truvelog Mix 30 will be available as a 100 U/ml suspension for injection [2].

Category

A biphasic suspension of 30% rapid-acting and 70% intermediate-acting human insulin analogue
Currently more than 4.9 million people in the UK are diagnosed with diabetes (90% type 2), and it is estimated that a further 850,000 people with type 2 diabetes have not yet been diagnosed [1].
Type 1 and 2 diabetes mellitus in adults, adolescents and children aged ≥10 years.
Subcutaneous injection